Karyopharm Therapeutics Inc. — FY2019 Form 10-K
Reporting period: Fiscal year ended December 31, 2019. The filing reports annual results, not standalone fourth-quarter results; Q4-specific financial values are not clearly provided in the supplied text.
Business context and reporting period
Karyopharm is a biopharmaceutical company developing and commercializing drugs targeting nuclear export. Its lead product, XPOVIO (selinexor), received FDA accelerated approval in July 2019 for a narrowly defined, heavily pretreated multiple myeloma population and launched in the United States that month. The approval is based on response rate and remains contingent on confirmatory evidence of clinical benefit.
Key financial metrics
| Metric | FY2019 | FY2018 |
|---|---|---|
| Product revenue, net | $30.5 million | None reported |
| License and other revenue | $10.4 million | $30.3 million |
| Total revenue | $40.9 million | $30.3 million |
| Cost of sales | $2.4 million | None reported |
| Research and development expense | $122.3 million | $161.4 million |
| Selling, general and administrative expense | $105.4 million | $48.8 million |
| Operating loss | $189.3 million | $179.9 million |
| Net loss | $199.6 million | $178.4 million |
| Basic and diluted net loss per share | $3.22 | $3.14 |
| Net cash used in operating activities | $190.8 million | $159.1 million |
Margins: A comparable annual gross margin is not presented. Cost of sales was $2.4 million against $30.5 million of product revenue, but excludes some XPOVIO manufacturing costs expensed before approval; the filing says approximately $2.7 million of such previously expensed inventory remained on hand at year-end.
Liquidity: At December 31, 2019, cash and cash equivalents were $128.9 million, short-term investments $133.1 million, and long-term investments $2.0 million, or approximately $264.0 million combined. Total current assets were $278.6 million and current liabilities $46.4 million. Management expected available cash, cash equivalents and investments to fund current plans for at least 12 months from the financial statement issuance date.
Debt and financing: The balance sheet reports convertible senior notes of $109.9 million net carrying value (principal $172.5 million; 3.00% coupon; due 2025) and a $73.6 million deferred royalty obligation. The royalty financing provided $75.0 million at initial closing in 2019; payments are tied to future product revenues and are subject to contractual minimums, caps and default/change-of-control provisions. The notes’ effective interest rate was 11.85%; FY2019 interest expense on the notes was $12.4 million. Total interest expense was $15.6 million.
Material changes versus the prior comparable period
- Total revenue increased to $40.9 million, driven by the first XPOVIO sales; license and other revenue fell by about $20.0 million, chiefly because FY2018 included Biogen and Ono upfront/license revenue.
- R&D expense decreased by $39.1 million, primarily from lower clinical trial, consulting and personnel costs.
- SG&A expense rose by $56.6 million, primarily from commercial launch staffing and activities.
- Net loss widened by $21.2 million, and operating cash use increased by $31.7 million.
- Other expense shifted from $1.5 million of income to $10.3 million of expense, mainly reflecting interest on the notes and royalty financing.
- Cash, cash equivalents and investments declined from approximately $330.2 million at year-end 2018 to $264.0 million at year-end 2019. The company raised capital through $46.2 million of at-the-market stock sales and $73.6 million net proceeds from the royalty financing.
Outlook, commentary, risks and unusual items
- Management expected 2020 R&D and SG&A expenses to increase, citing continued clinical development, regulatory work and commercialization. No quantified revenue, earnings or cash-flow guidance is provided.
- The Phase 3 BOSTON multiple myeloma trial was expected to report top-line data in early 2020 and was intended to serve as the XPOVIO confirmatory trial. Failure to confirm benefit could jeopardize continued accelerated approval.
- The EMA had outstanding questions on the selinexor multiple myeloma application; the company expected a decision in mid-2020 after receiving additional time to respond.
- The FDA accepted the DLBCL supplemental application for priority review, with a stated target decision date of June 23, 2020. Approval was uncertain; additional confirmatory studies were planned if the application succeeded.
- Management highlighted commercialization, reimbursement, safety and tolerability, clinical trial outcomes, regulatory decisions, financing needs and third-party manufacturing as material risks. Selinexor’s commonly reported adverse events include thrombocytopenia, fatigue and gastrointestinal effects.
- The company reported securities class action complaints concerning disclosures about the SOPRA and STORM studies; it disputed the allegations and intended to defend the litigation. The filing does not provide a clear estimate of potential loss.
- Accelerated approval, increased launch-related costs, substantial continuing losses, and revenue-linked financing obligations are important features of the year. The company reported an accumulated deficit of $873.3 million.
Important facts for investors to verify
- Whether BOSTON results met the confirmatory requirements and what regulatory action followed for XPOVIO’s accelerated multiple myeloma approval.
- Subsequent FDA and EMA decisions on selinexor applications, including the DLBCL review and European multiple myeloma application.
- Commercial demand and net sales trends after launch, including channel inventory, prescriptions, payer coverage, rebates and returns.
- Cash burn, financing runway, debt service and the royalty agreement’s minimum-payment, revenue-share and collateral terms.
- Clinical safety, efficacy and enrollment updates for the broader selinexor pipeline, and whether planned trials and milestones were achieved.
- Developments in the securities litigation and any resulting financial exposure.